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Clinical codingElectronic health records (EHRs) offer the opportunity to ascertain clinical outcomes at large scale and low cost,
thus facilitating cohort studies, quality of care research and clinical trials. For acute myocardial infarction (AMI)
the extent to which different EHR sources are accessible and accurate remains uncertain.
Using MEDLINE and EMBASE we identiﬁed thirty three studies, reporting a total of 128658 patients, published
between January 2000 and July 2014 that permitted assessment of the validity of AMI diagnosis drawn from
EHR sources against a reference such as manual chart review. In contrast to clinical practice, only one study
used EHR-derived markers of myocardial necrosis to identify possible AMI cases, none used electrocardiogram
ﬁndings and one used symptoms in the form of free text combined with coded diagnosis. The remaining studies
reliedmostly on coded diagnosis. Thirty one studies reported positive predictive value (PPV)≥ 70% between AMI
diagnosis from both secondary care and primary care EHRs and the reference. Among ﬁfteen studies reporting
EHR-derived AMI phenotypes, three cross-referenced ST-segment elevation AMI diagnosis (PPV range 71–
100%), two non-ST-segment elevation AMI (PPV 91.0, 92.1%), three non-fatal AMI (PPV range 82–92.2%) and
six fatal AMI (PPV range 64–91.7%).
Clinical coding of EHR-derived AMI diagnosis in primary care and secondary care was found to be accurate in
different clinical settings and for different phenotypes. However, markers of myocardial necrosis, ECG and symp-
toms, the cornerstones of a clinical diagnosis, are underutilised and remain a challenge to retrieve from EHRs.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Information on clinical diagnoses and outcomes derived from elec-
tronic health records (EHRs) is of increasing relevance for both clini-
cians and researchers [1]. These records represent a rich source of
clinical information, collected at minimal cost, in large numbers of peo-
ple and with potential for linkage to other data sources [2]. Acute myo-
cardial infarction (AMI) represents an important clinical outcome, and
unlike many diseases, has internationally accepted andwell-deﬁned di-
agnostic criteria which are widely used in clinical practice [3]. EHRs
have been used in different types of research: to assess quality and per-
formance of healthcare providers for managing patients [4,5], to moni-
tor national trends in mortality and morbidity, along with intra and
inter-country comparisons of healthcare policy [6] and to generate out-
come data for prospective studies and clinical trials [7–10]. There is aformatics Research University
land Ltd. This is an open access articlegrowing interest in EHR phenotypes to gain insights into the aetiology
of AMI through “omic” association studies [11].
However there have been no systematic, contemporary evalua-
tions of the diverse sources of EHR data relevant for AMI ascertain-
ment, and of the validity of EHR data on AMI. In this context, EHRs
encompass any electronic source of information relevant to the def-
inition of AMI, including hospital EHRs containing clinical details
such as markers of myocardial necrosis values, electrocardiogram
(ECG) data, and administrative data on diagnoses used for billing
purposes; registries (including disease and mortality registries);
and primary care EHRs.
We sought to (1) evaluate the extent to which electronically stored
information on markers of myocardial necrosis, ECG ﬁndings, symp-
toms and diagnoses has been used to ascertain AMI, (2) evaluate the ac-
curacy of such EHR information, in different clinical settings, countries
and for different phenotypes and (3) make recommendations where
improvements are required. In order to do so, we carried out a system-
atic review of contemporary studies according to MOOSE [12] and
PRISMA [13] guidelines.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Search strategies
We searched MEDLINE and EMBASE databases for studies reporting
on EHR-derived AMI diagnosis published between 1 January 2000 and
31 July 2014. Keywords for EHRs, AMI, sensitivity, speciﬁcity, positive
predictive value (PPV), markers of myocardial necrosis and ECG were
searched using Medical Subject Headings (MeSH) terms and combined
using Boolean operators as appropriate (Supplementary material
online, Appendix A).2.2. Inclusion criteria
Eligible studies (1)werepublishedafter theyear2000; (2) ascertained
information relevant to an AMI diagnosis available in EHRs; (3) com-
pared EHR data with manual chart review, or other relevant informa-
tion; and, (4) provided or had a calculable PPV (‘true’ diagnosis of AMI
in reference/all AMI diagnosed in EHRs). Where available, we report
the sensitivity and speciﬁcity.
The medical classiﬁcation systems used to identify AMI diagnosis
were International Classiﬁcation of Diseases revision 8 (ICD-8), ICD-9
(-CM, Clinical Modiﬁcation) [14] or ICD-10, Diagnosis-related Group
(DRG) [15], Current Procedural Terminology (CPT) [16], and in primary
care Read Codes [17] and International Classiﬁcation of Primary Care
(ICPC) [18]. Studies using unstructured data (free text) were also in-
cluded and studies published in a foreign language with an abstract in
English were translated by a native speaker.2.3. Study screening and data extraction
Two authors (BR and NKF) independently reviewed all abstracts for
eligibility and obtained full text studies where inclusion criteria were
met or there was uncertainty. Studies were excluded when both re-
viewers agreed the inclusion criteria were not met and conﬂicts were
resolvedbydiscussionwith a third author (RSP) to reach consensus. Ad-
ditional studies were identiﬁed by hand-searching reference lists. BR
and NKF extracted quantitative and qualitative data from eligible stud-
ies. Multiple publications from one study dataset were deemed eligible
where results were reported for two or more AMI phenotypes.2.4. Quantitative and qualitative measurements
Accuracy of AMI diagnosis in an EHR source compared to a reference
was assessed by PPV, which we deﬁned arbitrarily as high if equal to or
above 90% andmoderate if between 70 and 89%. TheWilsonmethod for
binomial proportions [19] was used in STATA 13.1 to calculate 95% con-
ﬁdence intervals (CI) for studies that did not report it. For calculated
values, decimal places were only reported when study sample sizes
(n) were equal to or above 200. Eleven quality criteria adapted from a
standardised checklist [13] were used to evaluate the quality of studies
included in this review (Supplementary material online, Appendix B).3. Results
The initial search strategy identiﬁed 2561 abstracts (Supplementary
material online, Appendix C). After excluding duplicates, 1862 abstracts
were reviewed for eligibility, with thirty three studies meeting the full
inclusion criteria, three of which were published in a foreign language
(Supplementary material online, Appendix D). A total of 128658 EHR-
derived AMI diagnosis were identiﬁed and cross-referenced, of which
18164 potential cases were validated using manual chart review.3.1. Clinical data features used for ascertainment and validation of AMI
Studies were grouped into three different groups according to the
EHR source from which AMI diagnosis was derived, with twenty three
studies cross-referencing AMI diagnosis from secondary care, four
from mortality registries and three from primary care. Despite being
collected and used for different purposes, studies using administrative
billing databases (13/23) and hospital databases (10/23) to identify
AMI diagnosis in secondary care EHRs were grouped together because
AMI diagnosis was mostly derived using the same clinical data feature
(ICD-coded diagnosis).
Only one study cross-referenced EHR-derived abnormal troponin
levels with ICD-9 coded diagnosis [20]. None of the studies used elec-
tronically stored ECG data (digital wave form, computer interpretation
or physician interpretation), while one used symptoms in the form of
free text, combined with coded diagnosis, to search EHR sources for
AMI cases (n = 213) [21]. Heriot et al. also used unstructured data to
search for AMI diagnosis in electronic databases (n=48) and compared
these with post-mortem diagnosis obtained from autopsy reports [22].
Remaining studies relied on amixture of structured data from coded ad-
mission and/or discharge diagnosis and death certiﬁcates (Fig. 1).
Chart review was the preferred reference against which EHR-
derived AMI diagnosis was compared (24/33), despite ﬁve studies
reporting concerns over the lack of completeness of medical charts.
Other references included disease and mortality registries, question-
naires sent to general practitioners, autopsy ﬁndings and computerised
algorithms based on information obtained frommedical charts (Supple-
mentary material online, Appendix E). Twenty nine studies obtained
cross referencing information onmarkers of myocardial necrosis, twen-
ty ﬁve on ECG ﬁndings and twenty one on clinical symptoms.
‘True’ AMI status was mostly based on the WHO MONICA [23]
criteria (10/33), or the Joint European Society of Cardiology (ESC)/
American College of Cardiology (ACC) Committee [24] and American
Heart Association (AHA) Council on Epidemiology and Prevention [25]
criteria (9/33). Other criteria are listed on the Supplementary material
online, Appendix E.
3.2. Algorithms used to deﬁne EHR-derived AMI diagnosis
Studies used a range of coding algorithms to ascertain AMI diagnosis
in EHRs. Eighteen studies conﬁned the search to ICD-10 code I21 and/or
ICD-9 code 410, four combined those with codes for subsequent acute
myocardial infarction (ICD-10 code I22 or ICD-9 code 412), while ﬁve
also used other forms of acute ischaemic heart disease (ICD-9 codes
411, 413, 414 or ICD-10 codes I20 and I24) in their search algorithm.
Studies that ascertained STEMI and NSTEMI from hospital EHR used al-
gorithms based on a combination of ICD codes to account for the lack of
a speciﬁc ICD-9 and ICD-10 code for these events (Supplementarymate-
rial online, Appendix E).
3.3. PPV of AMI diagnosis in EHR sources (Fig. 2)
Twenty three studies ascertained AMI diagnosis from a secondary
EHR source against a non-electronic reference. Of those, twenty used
chart review as reference and nineteen reported moderate to high
PPVs (range 76–100%). Despite observing low PPV (20.7%), Gonski
et al. [20] found high sensitivity (100%), speciﬁcity (78.4%) and negative
predictive value (NPV) (100%) when comparing troponin levels in elec-
tronically stored troponin lists to ICD-coded AMI discharge diagnosis
derived from chart review. The three studies that did not use chart
review as reference observed the lowest PPVs (≤75%). Two used a
computerised algorithm based on information extracted by chart re-
view, of which one reported a PPV of 40% [26].
PPVs for the three studies that compared AMI diagnosis in primary
care EHRs with a reference varied between 75.0% and 96.6%, while
four studies using mortality registries found PPV between 67.1% and
Fig. 1.Comparisonof clinical data features drawn fromEHR and reference. Circle sizes represent thenumber of studies that used oneormore features in EHR and in reference. Studies using
several features appear more than once. For example, if a study used ICD-10 codes to identify AMI diagnosis in EHR and cross-referenced with non-troponin markers of myocardial ne-
crosis, ECG and symptoms derived from chart review, this study would count towards the ﬁnal number of studies on the ‘ICD codes; diagnosis’ row with the ‘other markers’ column,
the ‘researcher interpretation or not speciﬁed’ ECG column and the ‘clinical text; symptoms’ column.
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electronic source such as disease registry and reported high PPVs
(range 82–97%). Only two studies, both from Denmark, ascertained
AMI cases from disease registries and reported high PPVs (93.6% and
100%).
3.4. Phenotypes of EHR-derived AMI diagnosis (Fig. 3)
We found three studies that used EHR-derived STEMI events (PPV
range 71–100%), of which two ascertained both STEMI and NSTEMI
ﬁnding slightly higher PPVs for NSTEMI events (91% and 92.1% as
opposed to 79.2% and 88.1% for STEMI) [27,28]. The third study cross-
referenced STEMI diagnosis in three different countries, reporting
lower PPV for the Italian primary care EHRs (PPV 71.4%) compared to
both the Dutch primary care (PPV 92.6%) and Danish secondary care
EHRs (PPV 100%) [21].
Three studies validated EHR-derived non-fatal AMI diagnosis and re-
ported high PPVs (range 82–92.2%), while diagnosis of fatal AMI was
generally found to be less accurate (PPV range 64–91.7%). A possible ex-
planation for this ﬁnding is that fatal AMI included unheralded AMI and
events occurring outside hospital settings, where potentially less infor-
mationwas available to validate the AMI diagnosis and, therefore, these
cases could not be conﬁrmedwhen applying the criteria adopted by the
study. Additionally, sudden unexplained deaths might have been inac-
curately classiﬁed as fatal AMI, particularly when occurring outside
the hospital. In order to explore these possibilities, we further stratiﬁed
fatal AMI into in-hospital (death after admission to the hospital) and
out-of-hospital (OOH) AMI deaths. OOH deaths were deﬁned as those
that occurred outside hospital care such in emergency care (before ad-
mission to hospital), in residential care homes and dead-on-arrivalcases.We found that in-hospital AMI deathsweremore accurately diag-
nosed in EHRs (PPV range 74–91.7%) than OOH AMI deaths (PPV range
64–88.7%). However, additional studies are needed to investigate this
hypothesis as we found very few studies validating these phenotypes.
Incident AMI diagnosis was validated by seven studies (PPV range
72.7–97%), though case deﬁnitions adopted by the studies varied from
no previous AMI ever to no record of AMI in the previous 8 years.
3.5. International comparisons
We found thirteen studies ascertaining EHR-derived AMI diagnosis
from countries across Europe, ten from the United States (USA), three
from Canada, two from Australia, two from Brazil, and two from South
Korea. Accuracy of AMI diagnosis was similar between the majority of
studies published in the USA (PPV range 73.0–96.7%) and Europe (PPV
range 72.7–100.0%).When comparing EHRs in three different countries,
Coloma et al. found higher PPV for AMI diagnosis in the Italian primary
care database (PPV 96.6%) and the Danish secondary care registry
(100%) than in the Dutch primary care database (PPV 75.0%), despite
signiﬁcant differences in coding algorithms [21].
4. Discussion
Among thirty three studies ascertaining over 120000 potential AMI
events we found that diagnoses (mostly from administrative EHRs) had
moderate to high PPVs when cross referenced against chart review or
another EHR source. These results, however, are limited by signiﬁcant
heterogeneity and lack of standardisation between studies, both in the
reference adopted and in the clinical data features used to deﬁne AMI
in the EHR source and in the reference. EHR curated troponin values,
Fig. 2. PPV (with 95% CI) of studies using AMI diagnosis in an EHR source. Studies validatingmultiple EHR sources were includedmore than once. α Reference= computerised algorithm;
β Reference = questionnaire; γ Reference = registry; δ Reference = autopsy; * Marker = markers of myocardial necrosis; ¥ Details available in Supplementary material online,
Appendix 5; + 95% CI calculated using the Wilson method for binomial proportions.
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the internationally agreed and implemented deﬁnition [3] –were rarely
used to identify AMI patients electronically. The use of administrative
billing codes only is not optimal as they do not represent the true pa-
tient state but a reﬂection of it through the data recording process of
the healthcare workﬂow. If readily available, detailed phenotypic
biomarkers can be used to re-construct AMI diagnosis according to
different deﬁnitions, decreasing heterogeneity and improving data
sharing between studies. Theseﬁndings emphasize the need to improve
the electronic capture of high quality data for use in clinical care and
reuse in research. Professional societies such as the ESC and AHA should
make clinical practice recommendations for the extraction and
harmonisation of hospital data to enhance the accuracy and depth of
AMI phenotyping as a pre-requisite to high quality care (Box 1).
Despite investment in hospital EHRs such as the HITECH Act [29],
rich phenotypic and clinical data held in hospital information systems
still remain largely inaccessible for research, primarily due to use of pro-
prietary platforms with restricted capabilities and/or access (Box 1).
Troponin quantiﬁcation has revolutionised diagnosis of AMI [30], espe-
cially NSTEMI, and lends itself to electronic and structured storagewith-
in any EHR system, yet we found only one study [20] that used this
information to identify AMI cases. Furthermore, application of standards
for reporting and storage of data [31] can rapidly facilitate sharing of
such data for research but are not widely used. In contrast, use of ECGﬁndings relates to a fundamental problem of data acquisition and stor-
age,with themajority of healthcare institutions still workingwith paper
copies rather than electronic, and unsurprisingly we found no studies
identifying AMI based on electronically stored ECG data in combination
with other clinical data features. National or regional initiatives in
conjunction with industry are needed to migrate to an electronic
system, as exempliﬁed by healthcare organisations such as Kaiser
Permanente introducing electronic ECG capture across sites in the USA
[32]. Access to ECG data in EHRs may also allow examination of other
relevant phenotypes [33,34], as exempliﬁed by the CHARGE consortium
[35], as well as the discovery of new ‘deeper’ electrocardiographic
phenotypes (Box 1).
A major problem in evaluating studies of EHR-derived AMI diagno-
ses is the implementation of a ‘gold standard’ for cross referencing
purposes. We identiﬁed few studies that could faithfully report against
a ‘gold standard’ i.e. against sources with complete information avail-
able to classify cases according to external, internationally agreed
criteria. The majority of the studies used manual chart review despite
it being well recognised that paper charts may not record troponin
levels, ECG or symptoms and four of the included studies did not report
the use of any of these features to conﬁrm AMI diagnosis. Furthermore,
none of the studies utilised procedure codes for primary PCI or throm-
bolysis as surrogate deﬁnitions of AMI to either ascertain or validate
an AMI diagnosis, despite being highly speciﬁc treatments for STEMI
Fig. 3.PPV (with 95% CI) of studies using AMI diagnosis in an EHR source stratiﬁedbypredeﬁned phenotypes. Studies validatingmultiple phenotypeswere includedmore than once. + 95%
CI calculated using the Wilson method for binomial proportions.
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which external criteria for AMI are used. For example, Barchielli et al.
[37] applied two sets of criteria to the same cohort and found that PPV
varied considerably (PPV 94.6% using AHA Council of Epidemiology and
Prevention [25] criteria; PPV 65.3% using WHO MONICA [23] criteria).
These ﬁndings further emphasize the importance of raw data onmarkers
of myocardial necrosis, ECG and symptoms in order to reconstruct AMI
according to different deﬁnitions, facilitating comparison of study results
and data sharing. Additionally, such information is essential when com-
bining multiple sources that used different classiﬁcation criteria and to
re-classify cases after revisions of the current deﬁnition of AMI.
We found few studies investigating the validity of diagnosis among
different AMI phenotypes, with most focusing on composite AMI despite
emerging data suggesting important differences in survival and outcomes
among those with different AMI phenotypes [38]. Association studies
using “omic” technology will beneﬁt from greater phenotyping of AMI
in order to derivemechanistic insights [11,39,40]. There are questions re-
garding the accuracy of diagnoses derived solely from death certiﬁcates
[41], with a recent systematic review reporting low accuracy for AMI di-
agnosis derived fromvital statistics databases [42].Whilewe foundbetter
agreement in studies published after 2000 using mortality registries, PPV
was still considerably lower than in those using other sources of EHRs.
This conclusion, however, is limited by the high level of heterogeneity be-
tween studies included in both groups and within each group.
Comparisons across different EHR sources and countries were
limited by the heterogeneity in the algorithms used to deﬁne
EHR-derived AMI diagnosis. These ﬁndings mirror those of a previ-
ous systematic review [43] and highlight the need forinternationally agreed phenotyping EHR algorithms, spanning clin-
ical coding systems, to be developed and used for deﬁning AMI
cases in EHRs [44,45].
AMI diagnoses derived from secondary care, used in the majority of
the studies we report on, are collected primarily for administrative pur-
poses, rather than as a clinical tool. As such theymay not reﬂect the true
patient state but rather the healthcare setting or speciﬁc coding pro-
cesses they occur in and may be inﬂuenced by ﬁnancial or other pres-
sures [46]. These processes are inherently subject to variability, poorly
documented and usually not entirely understood by researchers. Fur-
thermore the quality or accuracy of coding itself is also variable. In
some healthcare systems, coding is performed by clinicians while in
others non-clinical personnel follow a predeﬁned protocol. Thus, to im-
prove quality of diagnosis coding as well as comparability of studies,
coding processes should be integrated into clinical care according to
guidelines issued by relevant professional bodies. Contextual informa-
tion essential to understand the clinical data, such as laboratory refer-
ence values, units of measurements and assay methods, also should be
consistently documented and made available (Box 1). Similarly, addi-
tional information that might alter interpretation of the data, such as
renal function, evidence of infection, co-morbidities and medications,
should be systematically recorded and made accessible.
Importantly, data from a patient with AMI may be recorded in a
growing number of different EHR sources (primary care, secondary
care and registries) and this represents an opportunity to increase the
ascertainment and accuracy of AMI. Reassuringly, we found that AMI di-
agnosis extracted from coded primary care diagnosis is as reliable as
secondary care, supporting the combined use of such data. Thus, the
Box 1
Actions to improve the use of EHR data for health outcome assessment, using AMI as an example.
Stage in data
cycle
Specific for AMI
(n studies)
Barriers Actions
Clinical acquisition of data features used in diagnosis
Laboratory
blood
values
Troponin values (1); Data fragmented and stored in different
clinical information systems
Use of established standards (LOINC*)[31]
Not specified laboratory
values (1)
Reference values and normalised data schemas
Diagnostic
tests
Electrocardiogram (0) Proprietary, different machines; different access Develop mechanisms and platforms to
capture data electronicallyNot always stored in electronic format
Symptoms Chest pain (1) Text contains personal identifiers Real time text mining
Robust text anonymisation
Combination of clinical data features to ascertain patients with diagnosis
Algorithms None Mostly limited to use of diagnosis codes from
primary or secondary care
Standardised and shareable
Different coding systems and versions used
Contextual
information
None Largely not known, not systematically
recorded and often unclear
Centralised metadata portals and mechanisms
to record and disseminate contextual
information
Clinical coding process detached from clinical care Greater clinician input into coding and
documentation of process
EHR sources Primary care (3) Multiple EHR sources not systematically linked Combine multiple EHR sources for
better accuracySecondary care (27)
Disease registry (2)
Mortality registry (4)
The ‘barriers’ column depicts some of the obstacles currently hampering the availability of data in easily accessible and usable electronic format; the ‘actions’ column offers actions to over-
come the obstacles described in the previous column. *LOINC: Logical Observation Identifiers Names and Codes, internationally standardised database for identifying medical laboratory
observations
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ascertainment, despite some studies identifying low rates of concor-
dance [27,47].
We found that disease prevalence was underreported (3/33)
and most studies did not specify if cases were spontaneous AMI
(type 1), MI secondary to an ischaemic imbalance (type 2), cardiac
death due to MI (type 3) or procedure-related AMI (types 4 and
5) [3]. In addition, only a third of the studies reported sensitivity
and ﬁve calculated speciﬁcity. These ﬁndings indicate that there is
a clear need to standardise conducting and reporting of validation
studies.
This systematic review has limitations. Grey literature was not
searched and it is possible that relevant literature was missed. Stud-
ies were so heterogeneous that formal meta-analysis was not carried
out, and therefore we could not estimate the extent of publication
bias. Additionally, studies might have used some of the clinical data
features to ascertain or validate AMI despite these not being reported
so greater efforts are needed to standardise the reporting of valida-
tion studies.5. Conclusions
Clinical coding of EHR-derived AMI diagnosis in primary care and
secondary care has moderate to high accuracy in different clinical
settings and for different phenotypes. However, markers of myocardial
necrosis values, ECG ﬁndings and symptom descriptions, the corner-
stones of a clinical AMI diagnosis, are underutilised and remain a
challenge to access and retrieve from EHRs. Efforts are needed to tackle
the barriers that currently impede optimised, and more accurate, use of
EHRs for AMI ascertainment.
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